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Other names: MUC3; mucin-17; mouse Muc3; small 
intestinal mucin MUC3; membrane mucin 17; secreted 
mucin 17; intestinal membrane mucin MUC17 
Location: 7q22.1 
Note: Mucin glycoproteins are a diverse family of high 
molecular mass, heavily glycosylated proteins 
differentially expressed in epithelial tissues of the 
gastrointestinal, reproductive and respiratory tracts. 
Membrane mucins such as MUC17 are expressed by 
epithelial cells to provide protection, maintain luminal 
structure, and provide signal transduction. Often these 
molecules are over- or aberrantly expressed in cancers 
of epithelial origin. Mucins confer anti-adhesive 
properties in cancer cells that lose their apical/basal 
polarization. They also provide adhesive properties 
towards endothelial cells favoring dissemination of 
mucin expressing cancer cells. 
MUC17 is a recently fully characterized mucin that 
belongs to the membrane-bound subfamily of mucin 
(Moniaux et al., 2006). It is a cell surface glycopr tein 
that is found on epithelial cells in select tissues of the 
body (wade need to precise the know profile). Its 
structure consists of an extracellular domain that 
extends above the cell surface and an intracellular 
domain of 80 amino acid residues. New evidence 
suggests its de-regulation in pancreatic cancer 
(Moniaux et al., 2006; Moehle et al., 2006). The first 
partial length cDNA sequence, now known to 
correspond to MUC17, was identified by Van Klinken 
et al. (1997). At that time, van klinken isolated a 
chimeric cDNA clone overlapping MUC3 specific 
tandem repeat sequence and a new 59 aa sequence  
repeated in tandem. This sequence was therefore 
believed to be part of MUC3 until Gum and 
collaborators identified the carboxy terminal sequence 
of the 59 aa tandem repeat and identified this sequence 
has part of a new mucin called MUC17. Indeed, in 
2002, driven with the hypothesis that the 177 bp 
tandem repeated sequences were part of a new 
unidentified mucin, Gum et al. screened the public 
GenBankTM database and the proprietary Lifeseq Gold 
database (Incyte Genomics Inc., CA). By database 
searching and RT-PCR they extended the partial mucin 
sequence found during analysis of MUC3 and cloned a 
MUC17 fragment of 3,807 bp (accession number 
AF430017) (Gum et al., 2002). In 2006, Moniaux and 
Junker reported the complete coding sequence and 
organization of the MUC17 gene (Moniaux et al., 
2006). 
DNA/RNA 
Note: MUC17 was identified and localized to 
chromosome 7q22 by radiation hybridization mapping 
(Gum et al., 2002) where it resided in a gene cluster 
with mucins MUC3A, MUC3B, and MUC11/12 
(Figure 1). These mucins reside next to each other and 
have function in intestinal epithelium integrity, but are 
expressed in other different tissues and likely have 
different functions as well. The mucin genes within the 
cluster are transcribed independent of one another. 
MUC17 shows a low degree of VNTR (variable 
number of tandem repeats) polymorphism with only 
three different genomic DNA sizes detected for the 
large tandemly repeated extracellular domain in 24 
cancer lines (pancreas, colon, and breast) and in four 
healthy individuals control samples (Moniaux et al., 
2006). 
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Figure 1 - Chromosome location within the 7q22 mucin gene cluster. 
MUC17 resides in a gene cluster with mucins MUC3A, MUC3B, and MUC11/12 on chromosome 7 in the region q22.1. Upstream of the 
gene cluster 50 Kb is a potential open reading frame that shares similarity to MUC3. Approximately 26.7 Kb downstream of MUC17 
reside TRIM56 and SERPINE1. Less that 1.2 Kb of genomic distance separates the 3' end of MUC12 from the beginning of MUC17. 
Figure 2 - MUC17 genomic and transcript bp size. 
The MUC17 gene encompasses (38,587 bp) 38.6 Kb of genomic sequence. The coding sequence contains 13 exons and is transcribed 
as a (14,360 bp) 14.4 Kb RNA that gives rise to full-length MUC17. The presence of an alternative splice site results in exclusion of exon 
7, and produces a processed RNA that gives rise to a shorter MUC17/SEC. 
Description 
Radiation hybridization mapping was performed using 
the GeneBridge4 radiation hybrid panel (Research 
Genetics, Huntsville, AL). Following hybridization, the 
MUC17 probe was detected in the panel of 93 
independent human/hamster fusion clones with 
MUC17 specific primers, and data were analyzed using 
the GeneBridge4 server. This analysis indicated linkage 
to markers on chromosome 7q22 with an LOD score of 
15. The presence or absence of MUC17 was 
concordant with STS (Sequence Tagged Site) marker 
D7S666 in 83 of 84 panel DNA samples that were 
unambiguous for both markers, thus positioning 
MUC17 near base 101,250,000 of chromosome 7 using 
the National Center for Biotechnology Information 
(NCBI) STS map. The NCBI electronic PCR server 
refined the interval to bases 98,871,000 and 99,054,0 0 
of the STS map and positioned MUC17 approximately 
2,000,000 bases telomeric of MUC3A on 7q22 (Gum et 
al., 2002). 
The MUC17 sequence has now been extended toward 
its 5'-extremity to complete the sequence and localize 
the promoter and regulatory elements. Rapid 
amplification of cDNA ends (RACE) and sequences 
from the Human Genome databases were used. The 
MUC17 gene is located within a 39-kb DNA fragment 
between MUC12 and SERPINE1 on chromosome 7 in 
the region q22.1 (Moniaux et al., 2006). 
Transcription 
The MUC17 full-length coding sequence is transcribed 
as a (14,360 bp) 14.4 Kb mRNA encompassing 13 
exons from a (38,587 bp) 38.6 kb genomic fragment 
(Figure 2). Alternate splicing generates two variants 
coding for a membrane-anchored and a secreted form 
of the protein (Moniaux et al., 2006) (Figure 3). The 
presence of an alternative splice event/site in the 3'-
extremity of MUC17 was investigated by RT-PCR. 
RT-PCR was carried out on AsPC-1 cDNA. The 
generated amplification products were cloned into 
pCR® 2.1 and screened. Two distinct fragments were 
identified through sequencing. One of the fragments 
was 100% identical to the previous referenced 
sequence of MUC17 (accession number AJ606307). 
The second product revealed the occurrence of an 
alternative splice event that resulted in the skipping of 
exon 7. This alternative splice event generated a frame-
shift which coded for the 21 (MUC17/SEC) specific 
amino acid residues and introduced a stop codon 
positioned 66 nucleotides after the junction. The 
resulting protein encodes a secreted form of MUC17 
(accession number AJ606308), lacking the second EGF 
domain, the transmembrane domain and cytoplasmic 
tail (Figure 3). RT-PCR was carried out in four distinct 
cell lines, (pancreatic AsPC-1, and colonic LS174T, 
CaCo-2, and Ls180), representing different tissues, i. . 
pancreas and colon (Moniaux et al., 2006). Two 
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amplification products were detected. Sequencing of 
the major amplification product identified it as the 
MUC17 sequence described by Gum et al. (accession 
number AF430017), while the other amplicon (minor) 
corresponded to an alternatively spliced variant 
(skipping of exon 7), the secreted form of MUC17, 
referred to as MUC17/SEC. The level of expression of 
MUC17/SEC seemed very low in the cell lines 
investigated; the intensity of the corresponding band 
was very faint as compared to the MUC17 fragment 
(Moniaux et al., 2006). 
MUC17 is expressed in select cell lines including 
pancreatic AsPC-1 and HPAF-II; and colon cancer cell 
lines LS174T, Caco-2, NCI-H498, and HM3 (Gum et 
al., 2002; Moniaux et al., 2006). Tissue expression was 
first shown by RNA dot blot analysis (Clontech 
multiple tissue expression blot). MUC17 is expressed 
in intestinal tissues, with the highest levels found i  the 
duodenum (highest level) and in the transverse colon 
(85% of the level detected in duodenum). The only 
non-intestinal tissues found to express MUC17 in ths
analysis were stomach and fetal kidney. Both tissue 
showed approximately 7% of the expression level 
detected in the duodenum (Gum et al., 2002). In-situ 
hybridization was conducted to determine the cell 
specificity of MUC17 expression in the small intestine. 
In-situ hybridization showed MUC17 expression 
predominantly in the apical region of villi absorptive 
cells. Barely detectable expression was found in 
immature cells of the crypts. No expression was 
detected in goblet cells (Gum et al., 2002). Therefore, 
MUC17 expression is localized to the mature, 
absorptive cells of intestinal villi epithelium and is 
expressed in pancreatic cancer tissue (Moniaux et al., 
2006). 
The MUC17 gene is located within a 39 kb DNA 
fragment between MUC12 and SERPINE1 on 
chromosome 7. Approximately 1.2 Kb of sequence lies 
between the 3' end of MUC12 and the 5' UTR of the 
MUC17 gene. Expression of MUC17 is regulated by 
this 1,146-bp fragment upstream of MUC17 which 
contains various VDR/RXR, GATA, NFkB, and Cdx-2 
response elements. Like mouse Muc3 (mMUC3), 
regulation of expression is controlled by both growth 
factors and cytokines (unpublished data, Junker and 
Batra, 2007). The mMuc3 promoter has consensus 
binding sites for AP1, CREB, SP1, NF kappa B, GATA 
binding protein, and Cdx. Reporter constructs 
demonstrate that IL-4, IL-6, EGF, and PMA increase 
mMuc3 promoter activity 35-58% of control levels. 
TNF-a and IFN-g showed a lesser degree of stimulation 
(Shekels et al., 2003). Regulation of mMuc3 by 
cytokines and growth factors suggests an active role of 
mouse Muc3 and its human homologue, MUC17 in 
intestinal mucosal defense. 
A recent study conducted by Moehle et al. (2006) 
concerned the aberrant expression and allelic variants 
of mucin genes associated with inflammatory bowel 
disease (IBD). The aim of the study was to characteize 
changes in the expression profiles of genes related to 
intestinal epithelial function by comparing biopsy 
samples from patients with Ulcerative Colitis (UC) and 
Crohn's disease (CD), to controls; as the loss of 
intestinal mucosal integrity is an important factor in 
IBD. 
DNA-microarray analysis was applied and showed that 
mucin genes are differentially regulated in CD and UC. 
The loss of intestinal integrity is an important factor in 
the pathogenesis of inflammatory bowel disease. A 
coordinate down regulation of mucins was observed in 
a pool of biopsy RNAs (n=4) taken from affected and 
unaffected (control) regions of the terminal ileum and 
colon of CD and UC patients. No expression in the 
biopsy samples was detected for MUC6, MUC7, 
MUC8, MUC9, MUC11, MUC15, MUC16, and 
MUC18. Highest mucin expression values were 
displayed my MUC2, MUC13, and MUC17 in the 
ileum and the colon, while MUC12 was expressed in 
the colon. The relative expression levels for MUC1, 
MUC2, MUC4, MUC5B, MUC12, MUC13, MUC17, 
and MUC20 showed strong down regulation with 
decrease factors ranging from -1.3 to -48.5 fold. 
MUC17 showed a -4.3 and -2.6 fold decrease in 
Crohn’s disease and Ulcerative Colitis respectively in 
the colon, but showed an apparent increase of 1.2 and 
1.1 fold respectively in the same diseases in the ileum 
biopsy pooled RNAs. 
Real-time RT-PCR TaqMan assays were conducted to 
obtain a specific overview of mucin expression in 
human tissues. An initial analysis of nine mucin gees 
in a panel of 26 different tissues was completed. The
authors confirmed the relative expression values 
(average intensity) of DNA-microarray data (i.e., 
higher expression levels of MUC4, MUC5B, MUC12, 
and MUC20 were obtained in the colon compared to 
the ileum RNA; MUC17 was expressed higher in the 
ileum than in the colon). A meta-analysis of 11 
genome-wide linkage studies for IBD revealed 38 
significant IBD loci (Brant et al., 2004). Interestingly, 
all mucin family member loci reside within or directly 
beside these IBD candidate loci. Therefore, Moehle t 
al. performed allelic discrimination of one candidate 
exonic SNP within each mucin gene in UC (n=220), 
CD (n=181), and control (n=250) patient samples. 
Significant associations were detected for the MUC2, 
MUC4, and MUC13 mucin SNPs. The von Wildebrand 
Factor (vWF) domain of MUC2 (11p15, A/G, V116M) 
is associated with CD, the vWF domain of MUC4 
(3q29, G/T, A585S) with UC, and the cytoplasmic tail
domain of MUC13 (3q13.1, A/C, R502S) with UC. 
Unassessed SNPs in the mucin genes may still be 
associated and remain unchecked. 
The abundance of NFkB sites present in mucin 
promoters prompted the authors (Moehle et al., 2006) 
to explore regulation of mucin expression in the 
Ls174T colon cell line model. The ligands TNF-a, 
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TGFb, and LPS induced expression of MUC17 as 
assayed by quantitative real-time PCR. TNF-a was able 
to induce a time-dependent up-regulation of all the
monitored mucin genes (MUC-1, -2, MUC-5AC, -5B, -
12, -13, -17, -20). All monitored mucin genes showed 
increased expression with TGFb treatment. 
Cooperation of NFkB with TGFb signaling has been 
reported (Jono et al., 2002). Co-incubations of TGFb 
with NFkB pathway inhibitors (CAPE and MG132) 
resulted in a decrease of mucin expression, thus 
demonstrating a link between these two pathways with
regards to mucin gene regulation. 
Treatment of the Ls174T colon cancer cell line with 
sodium butyrate had little or no effect on induction f 
MUC17 expression level but did induce expression of 
MUC3 which is not highly expressed in the cell line 
(Gum et al., 2002). Similarly, incubation of MUC17 
non-expressing cell line, MiaPaCa, with HDAC 
inhibitor 5-aza-cytosine had little effect if any on 
MUC17 expression. 
Protein 
Note: 4493 aa; 425.5 kDa (note: without modification 
such as glycosylation) 
Description 
MUC17 is classified as a membrane-bound mucin 
glycoprotein. The protein may serve as a cellular 
receptor. The deduced full-length membrane-bound 
amino acid sequence (4493 aa) shows the presence of 
various mucin domains (Figure 3). A signal sequence  
targets the protein to the plasma membrane. The 
majority of the molecule encodes the mucin central 
domain that is modified extensively by glycosylation 
and is displayed on the extracellular face of the cell. 
The central domain of MUC17 contains 63 repeats of 
59 amino acid sequence (177 bp) that are repeated in 
tandem. This tandem repeat 'central domain' is 
followed by a region of unique degenerate tandem 
repeats and mucin-like sequences (i.e. that are 
repetitive, G/C rich, and contain a high content of 
threonine, serine, and proline amino acids). Two EGF-
like domains flank both sides of a SEA module and 
precede the transmembrane domain. Putative N-
glycosylation sites occur near the carboxyl terminus. 
The 80 amino acid C-terminal cytoplasmic domain has 
potential serine and tyrosine phosphorylation sites. 
Expression 
RNA blot analysis and RT-PCR suggests MUC17 is 
expressed in the digestive tract, primarily in the 
duodenum (highest level) and the transverse colon 
(85% of the level detected in duodenum) (Gum et al., 
2002). Expression is also reported in the terminal ileum 
(Moehle et al., 2006) with MUC17 expressed higher in 
the ileum than in the colon (quantitative RT-PCR, 
microarray analysis). Many colon and pancreatic 
cancer cell lines do express varied levels of MUC17 
(Gum et al., 2002; Moniaux et al., 2006). An over-
expression of MUC17 by Western blot and 
immunohistochemical analyses in pancreatic tumor cell 
lines and tumor tissues compared to normal pancreas 
samples is seen (Moniaux et al., 2006). 
 
Figure 3 - full length MUC17 and secreted MUC17/SEC. 
Full-length MUC17 contains a 25 amino acid leader peptide (secretion, membrane targeting signal), a central domain with tandemly 
repeated sequence, two EGF-like domains, a SEA domain, transmembrane domain, and an 80 amino acid cytoplasmic tail domain. 
Usage of an alternative splice site excludes exon 7 and introduces a frame shift that creates a premature stop codon 66 nucleotides 
after the splice junction, within the SEA domain coding sequence. This shorter transcript results in a secreted form of the protein, 
MUC17/SEC, which has 21 unique C-terminal amino acids, and lacks the second EGF domain, transmembrane domain, and C-terminal 
cytoplasmic tail.  
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Localisation 
Surface localization of the smaller subunit of MUC17 
is reported to be dependent on its N-glycosylation 
status (Ho et al., 2003). MUC17 contains a SEA 
domain, a transmembrane domain, and putative N-
glycosylation sites in the carboxyl terminus. Mucins 
that possess a SEA domain usually undergo an auto-
proteolytic cleavage event within the domain (Macao et 
al., 2006) to yield two subunits, the smaller of which is 
associated with the surface membrane. Ho and 
colleagues reported that the ASPC-1 pancreatic cancer 
cell line shows three main bands (38, 45, and 49 kDa) 
of immunoreactivity with an antibody directed against 
a site downstream of the postulated SEA cleavage site 
(Ho et al., 2003). Treatment with N-glycan specific 
hydrolases showed the 38 kDa band contained high 
mannose glycans, whereas the 45 and 49 kDa bands 
contained complex-type glycans. Surface biotinylation 
studies revealed that only forms possessing complex-
type N-glycans were localized to the cell surface. Both 
tunicamycin (N-glycosylation inhibitor) and brefeldin 
A (an inhibitor of protein transport) reduced surface 
localization. Surface localization of the smaller subunit 
of MUC17 therefore appears to be dependent on its N-
glycosylation status in AsPC-1 pancreatic cancer cells. 
Immunohistochemical analysis of mouse Muc3 (the 
homologue of MUC17) revealed strong staining in 
goblet cells and patchy staining of surface columnar 
cells in the duodenum, small intestine, caecum, colon 
and rectum (Shekels et al., 1998). Northern blot 
analysis indicates that the mRNA is approximately 13.5 
kb. Highest expression was detected in the caecum with 
lesser amounts detected in the colon and small 
intestine. No message was found in mouse stomach, 
trachea, lung, kidney, esophagus or pancreas (Shekels 
et al., 1998). In-situ hybridization studies show 
expression at the tips of villi, in the upper crypts, and in 
surface cells of the caecum and colon (Shekels et al., 
1998). 
Rodent (mouse) mMuc3 and (rat) rMuc3 are assumed 
to represent secretory mucins expressed in columnar 
and goblet cells of the intestine. In-situ hybridizat on 
with a 3'-probe localized (rat) rMuc3 expression 
generally to columnar cells. Two antibodies specific for 
the C-termini of rat rMuc3 localized the protein to 
apical membranes and cytoplasm of columnar cells. An 
antibody to the tandem repeat sequence, however, 
localized the protein to both columnar and goblet cells. 
Cesium chloride ultracentrifugation was used to isolate 
both light- and heavy-density fractions. A full-length 
membrane-associated form (light density) was found in 
columnar cells, whereas, the carboxyl-truncated soluble 
form of rat Muc3 (heavy density) was present in goblet 
cells (Wang et al., 2002). A similar localization of
human MUC17 may exist as the splice variant, 
MUC17SEC, encodes a truncated protein that is 
missing the second EGF-like domain, the 
transmembrane domain, and the cytoplasmic tail. The 
MUC17/SEC protein is believed to be a soluble protein 
as the absence of the transmembrane domain would 
result in its secretion from the cell. In a mouse model of 
human cystic fibrosis, both soluble Muc3 and goblet 
cell Muc2 are increased and hyper-secreted 
contributing to the excess intestinal mucus of cysti  
fibrosis mice (Khatri et al., 2001). 
Function 
MUC17 is a membrane-bound glycoprotein that may 
serve as a cellular receptor through its extended, 
repetitive extracellular glycosylation domain. The 
extracellular domain may serve a lubricant 
functionality and provide a signal transduction 
capability. Membrane mucins, such as MUC17, 
function in epithelial cells to provide cytoprotection, 
maintain luminal structure, provide signal transduction, 
and confer anti-adhesive properties to cancer cells 
which lose their apical/basal polarization. Outside-in 
signaling may be transduced by the protein's interac ion 
with extracellular matrix constituents including growth 
factors and cytokines and/or potentially binding of 
Ca2+ or EGF ligands to extracellular displayed EGF-
like domains. The 80 amino acid cytoplasmic domain 
has potential serine and tyrosine phosphorylation stes 
to convey extracellular signals. 
Analysis of mouse Muc3 showed that a definitive 
proteolytic cleavage occurs during processing in the
endoplasmic reticulum. Recombinant products 
consisted of a V5-tagged 30 kDa extracellular 
glycopeptide and a Myc-tagged 49 kDa membrane-
associated glycopeptide. Throughout their cellular 
transport to the plasma membrane, the two fragments 
remained associated by non-covalent SDS-sensitive 
interactions. Site-specific mutagenesis showed 
requirement for glycine and serine residues in the 
cleavage sequence Leu-Ser-Lys-Gly-Ser-Ile-Val-Val, 
which is found in the SEA domain between the two 
EGF-like motifs of the mucin. A similar cleavage 
sequence has been reported in human MUC1 and 
analogous sites are present in human MUC3, MUC12, 
MUC16 and MUC17. Proteolytic cleavage may be a 
conserved characteristic of the membrane-bound 
mucins, and possibly precedes the release of their large 
extracellular domains at cell surfaces (Wang et al., 
2002). 
Homology 
The similarity of human MUC17 to rodent Muc3 
(mouse and rat) was first reported by JR Gum Jr and 
colleagues. This similarity was represented by a 
cladogram calculated using sequences initiating at the 
start of the second EGF-like domain and continuing 
through to the carboxy-termini of the proteins. The 
analysis suggests that MUC17 diverged from human 
MUC3 earlier in evolution than the divergence of 
primates and rodents, and suggests that MUC17 is the 
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true structural homolog of rodent Muc3 (Gum et al.,
2002). Whether MUC17 is the functional homolog of 
rodent Muc3 is still unclear, however, and needs to be 
experimentally proven. Chromosome computer 
analysis assigns mouse Muc3 to mouse chromosome 5, 
a region of synteny to human chromosome 7, the 
location of the human MUC3, MUC12, and MUC17 
mucin genes. NCBI HomoloGene reports MUC17 is 
conserved in Coelomata or in organisms higher than 
coelenterates and certain primitive worms. 
Expression of the mouse Muc3 mucin has been 
characterized in terms of regulation of its promoter by 
cytokines and growth factors. Mouse Muc3 is now 
believed to be the true structural homologue of human 
MUC17 due to higher sequence similarity to MUC17  
than human MUC3 (Moniaux et al., 2006). The N-
terminal domain for MUC17 is coded by two exons, 
whereas for MUC3, it is coded by a single exon. Gum 
and colleagues (2002) showed that the degree of 
sequence homology between the carboxy-extremity of 
MUC17 and mMuc3 was higher than that between 
MUC3 and mMUC3. An alignment of the amino-
extremities of MUC17, MUC3, and mMuc3 is shown. 
No similarity is shown by MUC3 and mMuc3, but a 
high degree of identity exists between MUC17 and 
mMUC3. Their similar structural organization and high 
degree of identity show that MUC17 is the human 
homologue of mMuc3. 
A search of the National Center for Bioinformatics 
HomoloGene and UniGene databases returned the 
following suggested sequences for comparison. 
 
HomoloGene:88635. Gene conserved in Coelomata  
Human H. sapiens MUC17 mucin 17, cell surface associated, chromosome 7q22.1, GeneID: 140453 
Chimpanzee 
(West African) 
P. troglodytes MUC17 mucin 17, chromosome 7, GeneID: 740201 
Mouse M. musculus Muc3 mucin 3, intestinal 
Rhesus monkey Macaca mulatta   chromosome 3 
Human Homo sapiens CAE54435 membrane mucin MUC17 (Homo sapiens) 
gi/51869309/emb/CAE54435.1/(51869309) 
Human Homo sapiens CAE54436 secreted mucin MUC17 (Homo sapiens) 
gi/51869311/emb/CAE54436.1/(51869311) 
Human Homo sapiens AAL89737 intestinal membrane mucin MUC17 (Homo sapiens) 
gi/19526645/gb/AAL89737.1/AF430017_1(19526645) 
Human Homo sapiens AAI26316 MUC17 protein (Homo sapiens) gi/118835615/gb/AAI26316.1/(118835615) 
Human Homo sapiens NP_001035194 mucin 17 (Homo sapiens) gi/91982772/ref/NP_001035194.1/(91982772) 
Chimpanzee 
(West African) 












PREDICTED: similar to MUC17 protein (Monodelphis domestica) 
gi/126309309/ref/XP_001371346.1/(126309309) 
Chicken Gallus gallus XP_001233667 PREDICTED: similar to intestinal membrane mucin MUC17, partial 
(Gallus gallus) gi/118121828/ref/XP_001233667.1/(118121828) 






LOC100017948 similar to MUC17 protein (Monodelphis domestica) , Chromosome: 2, 
GeneID: 100017948 





LOC100023779 similar to membrane mucin MUC17 (Monodelphis domestica), 
Chromosome: 3, GeneID: 100023779 
Chimpanzee 
(West African) 




Rattus norvegicus Muc17_predicted Muc17_predicted and Name: mucin 17 (predicted) (Rattus norvegicus), 
Chromosome: 7, GeneID: 295035 











Atlas Genet Cytogenet Oncol Haematol. 2008;12(3)  232 
Selected Protein Similarities  
Comparison of sequences in UniGene with proteins supported by a complete genome. The alignments can suggest function of a gene. 
C. elegans 32.92 % / 636 aa ref:NP_505150.1 - reverse transcriptase (Caenorhabditis elegans) 
S. cerevisiae 30.55 % / 644 aa pir:S48478 - S48478 glucan 1,4-alpha-glucosidase 
R. norvegicus 27.24 % / 647 aa pir:A53577 - A53577 ascites sialoglycoprotein 1 - rat 
M. musculus 24.77 % / 633 aa ref:NP_035871.1 - zonadhesin (Mus musculus) 
A. thaliana 23.94 % / 531 aa ref:NP_564694.1 - expressed protein (Arabidopsis thaliana) 
D. melanogaster 22.31 % / 637 aa sp:Q02910 - CPN_DROME CALPHOTIN 





Worldwide, pancreatic cancer is the eleventh most 
common cancer. In the United States of America, 
pancreatic cancer is the fourth leading cause of cancer 
related death. Pancreatic cancer presents a 5-year 
survival rate of just 5%. The incidence and age-
adjusted mortality rate (approximatively 95%) are 
almost equal, underscoring the aggressive nature of the 
disease. 
Prognosis 
Currently, no approved diagnostic biomarker for 
pancreatic cancer is licensed in the United States. The 
CA19-9 mucin epitope is used for the diagnosis of 
ovarian cancer and other mucins are being developed 
for the detection of breast cancer (MUC1) and 
pancreatic cancer (MUC1, MUC4, MUC3, MUC17). 
The DUPAN-2 antibody recognizes a tumor-associated 
antigen carried by the MUC4 protein and is used as a 
clinical diagnostic for pancreatic adenocarcinoma in 
Japan. MUC4 is aberrantly expressed in 80% of 
pancreatic adenocarcinomas and is not expressed in the 
normal pancreas or benign pancreatitis. In addition 
MUC4 is expressed early in the onset of pancreatic 
cancer (detected in pancreatic intraepithelial neoplasia 
(PanIN) stage I disease). Similarly, MUC17 is 
aberrantly expressed in pancreatic adenocarcinomas as 
compared to no expression in the normal pancreas or 
benign pancreatitis. MUC17 is expressed early in the 
progression of pancreatic cancer with localization t  
well defined pancreatic ductal structures undergoin 
malignant transformation (Moniaux et al., 2006). 
Oncogenesis 
In an in vivo model, subcutaneous injection of MUC17 
AsPC-1 knock-down cells show slight increase in 
tumorigenicity in relation to parental control cells; 
although no significant difference was detected dueto 
large variation in tumor weights. A xenograph model 
with knock-down cell lines injected orthotopically into 
the pancreas head showed an increased potential to 
metastasize to the peritoneal cavity and increased 
tumor mass (weight) in relation to mice injected with 
the parental cell line (control group) transfected with a 
scrambled RNAi sequence (unpublished data, Junker 
and Batra, 2007). 
To be noted 
Note: Conserved in Coelomata. From (HomoloGene: 
88635. Gene conserved in Coelomata). 
Coelome: the cavity within the body of all animals 
higher than the coelenterates and certain primitive 
worms, formed by the splitting of the embryonic 
mesoderm into two layers. In mammals, the coelome 
forms the peritoneal, pleural, and pericardial cavities. 
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